The Oncosearch | Oncotarget

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer Research Paper

Saeed Rafii, Charlie Gourley, Rajiv Kumar, Elena Geuna, Joo Ern Ang, Tzyvia Rye, Lee-May Chen, Ronnie Shapira-Frommer, Michael Friedlander, Ursula Matulonis, Jacques De Greve, Amit M. Oza, Susana Banerjee, L. Rhoda Molife, Martin E. Gore, Stan B. Kaye, Timothy A. Yap

Published Apr 10, 2017 · Vol. 8, No. 29 · pp. 47154-47160

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer Clinical Research Papers

Jung-Min Lee, John L. Hays, Victoria L. Chiou, Christina M. Annunziata, Elizabeth M. Swisher, Maria I. Harrell, Minshu Yu, Nicolas Gordon, Tristan M. Sissung, Jiuping Ji, William D. Figg, Lori Minasian, Stanley Lipkowitz, Bradford J. Wood, James Doroshow, Elise C. Kohn

Published Mar 25, 2017 · Vol. 8, No. 45 · pp. 79175-79187

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells Research Paper

Francesco Morra, Francesco Merolla, Virginia Napolitano, Gennaro Ilardi, Caterina Miro, Simona Paladino, Stefania Staibano, Aniello Cerrato, Angela Celetti

Published Mar 22, 2017 · Vol. 8, No. 19 · pp. 31815-31829

Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity Research Paper

Catherine M. Nickson, Parisa Moori, Rachel J. Carter, Carlos P. Rubbi, Jason L. Parsons

Published Mar 16, 2017 · Vol. 8, No. 18 · pp. 29963-29975

The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition Research Paper

Erin N. McAndrew, Chloe C. Lepage, Kirk J. McManus

Published Nov 26, 2016 · Vol. 7, No. 52 · pp. 87417-87430

Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples Research Paper

Cindy Badoer, CÃ©line Garrec, Dirk Goossens, Gillian Ellison, John Mills, MÃ©lina Dzial, Hakim El Housni, Sarah Berwouts, Paola Concolino, Virginie Guibert-Le Guevellou, Capucine Delnatte, Jurgen Del Favero, Ettore Capoluongo, StÃ©phane BÃ©zieau

Published Oct 25, 2016 · Vol. 7, No. 49 · pp. 81357-81366

FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort Research Paper

Jeff Johnson, Michael Choi, Farnaz Dadmanesh, Bingchen Han, Ying Qu, Yi Yu-Rice, Xiao Zhang, Sanjay Bagaria, Clive Taylor, Armando E. Giuliano, Farin Amersi, Xiaojiang Cui

Published Sep 30, 2016 · Vol. 7, No. 46 · pp. 75729-75738

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas Research Paper

MaÅ‚gorzata CzyÅ¼, Monika Toma, Anna Gajos-Michniewicz, Kinga Majchrzak, Grazyna Hoser, Janusz Szemraj, Margaret Nieborowska-Skorska, Phil Cheng, Daniel Gritsyuk, Mitchell Levesque, Reinhard Dummer, Tomasz Sliwinski, Tomasz Skorski

Published Sep 27, 2016 · Vol. 7, No. 46 · pp. 75551-75560

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition Research Paper

Junko Murai, Ying Feng, Guoying K. Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier

Published Sep 27, 2016 · Vol. 7, No. 47 · pp. 76534-76550

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines Research Paper

Hubert Fleury, Euridice Carmona, Vincent G. Morin, Liliane Meunier, Jean-Yves Masson, Patricia N. Tonin, Diane Provencher, Anne-Marie Mes-Masson

Published Jun 27, 2016 · Vol. 8, No. 25 · pp. 40152-40168

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2 Research Paper

Mateusz Rytelewski, Saman Maleki Vareki, Lingegowda S. Mangala, Larissa Romanow, Dahai Jiang, Sunila Pradeep, Christian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Rene Figueredo, Peter J. Ferguson, Mark Vincent, Anil K. Sood, James D. Koropatnick

Published Mar 3, 2016 · Vol. 7, No. 15 · pp. 20825-20839

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer Research Paper

Dong Wang, Min Wang, Nan Jiang, Yuan Zhang, Xing Bian, Xiaoqing Wang, Thomas M. Roberts, Jean J. Zhao, Pixu Liu, Hailing Cheng

Published Feb 21, 2016 · Vol. 7, No. 11 · pp. 13153-13166

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response Research Paper

Stephanie Wurster, Fabian Hennes, Ann C. Parplys, Jasna I. Seelbach, Wael Y. Mansour, Alexandra Zielinski, Cordula Petersen, Till S. Clauditz, Adrian MÃ¼nscher, Anna A. Friedl, Kerstin Borgmann

Published Jan 19, 2016 · Vol. 7, No. 9 · pp. 9732-9741

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing Priority Research Paper

Andrea Mafficini, Michele Simbolo, Alice Parisi, Borislav Rusev, Claudio Luchini, Ivana Cataldo, Elena Piazzola, Nicola Sperandio, Giona Turri, Massimo Franchi, Giampaolo Tortora, Chiara Bovo, Rita T. Lawlor, Aldo Scarpa

Published Jan 7, 2016 · Vol. 7, No. 2 · pp. 1076-1083

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors Research Paper

Junhui Wang, Qianshan Ding, Hiroaki Fujimori, Akira Motegi, Yoshio Miki, Mitsuko Masutani

Published Dec 22, 2015 · Vol. 7, No. 7 · pp. 7701-7714

Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications Research Paper

See-Hyoung Park, Kyu Yun Jang, Min Jae Kim, Sarah Yoon, Yuna Jo, So Mee Kwon, Kyoung Min Kim, Keun Sang Kwon, Chan Young Kim, Hyun Goo Woo

Published Nov 2, 2015 · Vol. 6, No. 42 · pp. 44819-44831

E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling Research Paper

Sharon McGonigle, Zhihong Chen, Jiayi Wu, Paul Chang, Donna Kolber-Simonds, Karen Ackermann, Natalie C. Twine, Jue-lon Shie, Jingzang Tao Miu, Kuan-Chun Huang, George A. Moniz, Kenichi Nomoto

Published Oct 20, 2015 · Vol. 6, No. 38 · pp. 41307-41323

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis Clinical Review

Zhengqiang Bao, Chao Cao, Xinwei Geng, Baoping Tian, Yanping Wu, Chao Zhang, Zhihua Chen, Wen Li, Huahao Shen, Songmin Ying

Published Sep 22, 2015 · Vol. 7, No. 7 · pp. 7629-7639

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Research Paper

JosÃ© Luis OrdÃ³Ã±ez, Ana Teresa Amaral, Angel M. Carcaboso, David Herrero-MartÃn, MarÃa del Carmen GarcÃa-MacÃas, Vicky Sevillano, Diego Alonso, Guillem Pascual-Pasto, Laura San-Segundo, Monica Vila-Ubach, Telmo Rodrigues, Susana Fraile, Cristina Teodosio, AgustÃn Mayo-Iscar, Miguel Aracil, Carlos MarÃa Galmarini, Oscar M. Tirado, Jaume Mora, Enrique de Ãlava

Published May 27, 2015 · Vol. 6, No. 22 · pp. 18875-18890

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity Priority Research Paper

Jessica Frankum, Pavel Moudry, Rachel Brough, Zdenek Hodny, Alan Ashworth, Jiri Bartek, Christopher J. Lord

Published Mar 18, 2015 · Vol. 6, No. 13 · pp. 10746-10758

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer Research Paper

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer Clinical Research Papers

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells Research Paper

Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity Research Paper

The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition Research Paper

Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples Research Paper

FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort Research Paper

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas Research Paper

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition Research Paper

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines Research Paper

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2 Research Paper

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer Research Paper

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response Research Paper

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing Priority Research Paper

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors Research Paper

Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications Research Paper

E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling Research Paper

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis Clinical Review

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Research Paper

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity Priority Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer Research Paper

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer Clinical Research Papers

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells Research Paper

Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity Research Paper

The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition Research Paper

Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples Research Paper

FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort Research Paper

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas Research Paper

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition Research Paper

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines Research Paper

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2 Research Paper

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer Research Paper

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response Research Paper

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing Priority Research Paper

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors Research Paper

Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications Research Paper

E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling Research Paper

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis Clinical Review

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Research Paper

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity Priority Research Paper